Gastroesophageal Junction Cancer News

FDA Approval

FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors

10/18/2024

Stephanie Holland ;

Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...

Based on results from the...

10/18/2024

Oncology

News

Addition of Relatlimab to Nivolumab and Chemotherapy Did Not Improve Response Among Patients With Unresectable, Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer

05/23/2024

Stephanie Holland

According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...

According to results from the...

05/23/2024

Oncology

News

Pembrolizumab Plus Chemotherapy Approved for Patients With HER2-Negative Gastric or Gastroesophageal Junction Cancer

11/17/2023

Allison Casey ;

On November 16, 2023, the FDA granted approval to pembrolizumab plus chemotherapy for the treatment of patients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer in the first-line setting.

On November 16, 2023, the FDA...

11/17/2023

Oncology

News

Trastuzumab Plus Ramucirumab and Paclitaxel Shows Promise Among Patients With Second-Line HER2-Positive, Advanced Gastric or Gastroesophageal Junction Cancer

08/10/2023

Allison Casey ;

In a phase 1b/2 study, trastuzumab plus ramucirumab and paclitaxel showed promise in the second-line setting for patients with HER2-positive gastric or gastroesophageal junction cancer.

In a phase 1b/2 study,...

08/10/2023

Oncology

News

Frontline Tislelizumab Plus Chemotherapy for Patients With Gastroesophageal Squamous Cell Carcinoma

05/23/2023

In a phase 3 trial, tislelizumab plus chemotherapy improved the overall survival of patients with advanced or metastatic gastroesophageal squamous cell carcinoma when compared with placebo plus chemotherapy.

In a phase 3 trial, tislelizumab...

05/23/2023

Oncology

News

Zolbetuximab Plus CAPOX Improves Survival in Gastric/Gastroesophageal Junction Cancers

03/25/2023

Amber Denham ;

Zolbetuximab in combination with chemotherapy increases survival in patients with first-line claudin-18.2-positive/HER2-negative locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Zolbetuximab in combination with...

03/25/2023

Oncology

News

Potential of Sintilimab Plus Apatinib and Chemotherapy in Gastric or Gastroesophageal Junction Cancer

03/20/2023

Allison Casey ;

In a phase 2 study, sintilimab plus apatinib and chemotherapy demonstrated anti-tumor activity and tolerable safety among patients with gastric or gastroesophageal junction cancer.

In a phase 2 study, sintilimab...

03/20/2023

Oncology

News

Perioperative Nivolumab Plus Ipilimumab for dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma

03/02/2023

Allison Casey ;

Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab was associated with high pathological complete response with no unexpected toxicities for patient with dMMR/MSI-H gastric/gastroesophageal junction adenocarcinoma.

Neoadjuvant nivolumab plus...

03/02/2023

Oncology

News

Adding Atezolizumab to Modified FOLFOX May Improve Response Rates in Gastroesophageal Junction Cancer

02/10/2023

Allison Casey ;

The addition of atezolizumab to modified FOLFOX in the perioperative setting was found to be safe and may improve response rates for patients with gastroesophageal junction cancer.

The addition of atezolizumab to...

02/10/2023

Oncology

News

Potential of Overlap Guiding Tube-Assisted Method of Esophagojejunostomy for Gastric/Gastroesophageal Junction Cancer

02/08/2023

Allison Casey ;

Study findings reveal the overlap guided tube-assisted method of esophagojejunostomy for gastric/gastroesophageal junction cancer is associated with reduced surgical difficulty vs the conventional method.

Study findings reveal the...

02/08/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology